Guo-fu H. Li

No. 1200 Cailun Road
Shanghai, 201203, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 58 publications

Response to Comment on: "Tebentafusp Versus Nivolumab Plus Ipilimumab for Metastatic Uveal Melanoma: An E-Value Sensitivity Analysis Assessing Effect of Unmeasured Confounders on Observational Associations".

Response to Comment on: "Tebentafusp Versus Nivolumab Plus Ipilimumab for Metastatic Uveal Melanoma: An E-Value Sensitivity Analysis Assessing Effect of Unmeasured Confounders on Observational Associations".

Journal: Clinical drug investigation

Published: July 24, 2025

Methodologic Considerations in Assessing Invasive Disease-Free Survival as a Surrogate End Point for Overall Survival in Trials for Early Breast Cancer.

Methodologic Considerations in Assessing Invasive Disease-Free Survival as a Surrogate End Point for Overall Survival in Trials for Early Breast Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 02, 2025

Disparities in Trends of Gastroenteropancreatic Neuroendocrine Tumor Incidence.

Disparities in Trends of Gastroenteropancreatic Neuroendocrine Tumor Incidence.

Journal: JAMA oncology

Published: May 22, 2025

Tebentafusp Versus Nivolumab Plus Ipilimumab for Metastatic Uveal Melanoma: An E-Value Sensitivity Analysis Assessing Effect of Unmeasured Confounders on Observational Associations.

Tebentafusp Versus Nivolumab Plus Ipilimumab for Metastatic Uveal Melanoma: An E-Value Sensitivity Analysis Assessing Effect of Unmeasured Confounders on Observational Associations.

Journal: Clinical drug investigation

Published: January 21, 2025

Pediatric off-label use and nonadherence management for nadolol: A mechanistic PBPK model incorporating ontogeny scaling from interracial adults to children.

Pediatric off-label use and nonadherence management for nadolol: A mechanistic PBPK model incorporating ontogeny scaling from interracial adults to children.

Journal: Journal of pharmaceutical sciences

Published: November 19, 2024

Long-term use of tenofovir disoproxil fumarate and increased fracture risk in elderly patients with chronic hepatitis B: An E-value sensitivity analysis.

Long-term use of tenofovir disoproxil fumarate and increased fracture risk in elderly patients with chronic hepatitis B: An E-value sensitivity analysis.

Journal: Journal of hepatology

Published: October 31, 2024

Control compounds for drug-induced liver injury evaluation: Evidence from Database of Adverse Event Notifications.

Control compounds for drug-induced liver injury evaluation: Evidence from Database of Adverse Event Notifications.

Journal: Journal of hepatology

Published: October 31, 2024

Non-Linear Trends in the Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) From 1990 to 2021.

Non-Linear Trends in the Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) From 1990 to 2021.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: October 21, 2024

Overall Mortality and Cardiovascular Mortality Associated With MAFLD+/NAFLD- Versus MAFLD-/NAFLD+: A Secondary Analysis.

Overall Mortality and Cardiovascular Mortality Associated With MAFLD+/NAFLD- Versus MAFLD-/NAFLD+: A Secondary Analysis.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: September 17, 2024

Predicting plasma protein binding of drugs in special populations: Are all models wrong, but can some be recalibrated, refined, and become more useful?

Predicting plasma protein binding of drugs in special populations: Are all models wrong, but can some be recalibrated, refined, and become more useful?

Journal: Journal of pharmaceutical sciences

Published: August 16, 2024

Ursodeoxycholic acid and COVID-19 outcomes: a cohort study and data synthesis of state-of-art evidence.

Ursodeoxycholic acid and COVID-19 outcomes: a cohort study and data synthesis of state-of-art evidence.

Journal: Expert review of anti-infective therapy

Published: July 08, 2024

Overall Survival Benefit with Sacituzumab Govitecan in Metastatic Breast Cancer: A Post Hoc Interaction Analyses of a Randomized Controlled Trail.

Overall Survival Benefit with Sacituzumab Govitecan in Metastatic Breast Cancer: A Post Hoc Interaction Analyses of a Randomized Controlled Trail.

Journal: Clinical drug investigation

Published: May 12, 2024

Showing 1-12 of 58

Last Updated: 09/26/2026